EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 382 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Belantamab Mafodotin–Containing Triplets Confer a Significant PFS Benefit Among Previously Treated... July 3, 2024 This Breast Cancer Patient Is Using Boudoir Photography to Reclaim Her... November 5, 2019 At NCI, A Robust and Rapid Response to the COVID-19 Pandemic April 17, 2020 Misdiagnosis: Her Doctor Dismissed Her Concerns For Months Then Told Her... June 2, 2020 Load more HOT NEWS A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and... COVID-19 vaccine and cancer – latest updates Rise in Brain Metastases Detected in Patients with Stage IV NSCLC... Researchers Discover New Way to Prevent Hair Loss During Chemotherapy Treatment
